MedTrace Logo

Effects of FES-Rowing in Neurological Disorders (FES-ROW)

NCT04821635 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2025-09-19

No results posted yet for this study

Summary

The main objective of this project is to measure the increase in aerobic physical and metabolic capacities with a 6-month training on a rower assisted by electrostimulation of lower limbs in a population of adults with traumatic paraplegia.

Conditions

  • Spinal Cord Injuries

Interventions

DEVICE

Rower assisted by electrostimulation (FES-ROW)

1. Pre-inclusion visit 2. Inclusion visit 3. Phase 1 Rower-FES with lower limbs (Month 0 to Month 3: M0-M3): Training on a rower with solicitation of the electrostimulated lower limbs only for a period of 3 months at the rate of 3 sessions of 30 minutes per week 4. Interim assessment visit at Month 3 (M3) 5. Phase 2 Rower-FES with lower limbs + upper limbs (Month 3 to Month 6: M0-M6): Training on with solicitation of the electrostimulated lower and upper limbs for a period of 3 months at the rate of 3 sessions of 30 minutes per week 6. Final assessment visit at Month 6 (M6) 7. End of clinical research visit, 3 months after the end of training (Month 9, M9)

Sponsors & Collaborators

  • University of Franche-Comté

    collaborator OTHER

  • Hospices Civils de Lyon

    collaborator OTHER

  • University of Lyon

    collaborator OTHER

  • UGECAM Rhône-Alpes

    lead OTHER

Principal Investigators

  • Julie R Di Marco, M.D · UGECAM SSR Val Rosay

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-30
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04821635 on ClinicalTrials.gov